Linde stock barely budges into year-end as Fed minutes loom

Linde stock barely budges into year-end as Fed minutes loom

NEW YORK, December 28, 2025, 22:39 ET — Market closed

  • Linde shares slipped 0.03% to $424.77 at the Dec. 26 close; last after-hours quote was $426.63. Wall Street Journal
  • Wall Street finished nearly flat in thin post-Christmas trading; materials led S&P 500 sectors. Reuters
  • Investors are watching Fed minutes due Dec. 30 and Linde’s next results, expected Feb. 5. Reuters

Linde plc shares ended the last U.S. session little changed, slipping 0.03% to $424.77 at the Dec. 26 close, according to Wall Street Journal market data. The stock was last quoted at $426.63 at 6:22 p.m. ET in after-hours trading, which is trading after the 4 p.m. close. Wall Street Journal

The industrial gases supplier moved in step with a broader materials bid as Wall Street “caught its breath” in thin post-Christmas trading, a Reuters report said. Materials was the strongest-performing sector among the S&P 500’s 11 groups. Reuters

Why it matters now: with only a handful of sessions left in 2025, investors are looking for momentum to carry through the year-end “Santa Claus rally” window — a seasonal stretch that covers the last five trading days of the year and the first two of the next. The period runs through Jan. 5, Reuters reported. Reuters

“We’re just simply catching our breath today after the holiday,” Ryan Detrick, chief market strategist at Carson Group, said. Reuters

On Friday, the Dow slipped 0.04%, the S&P 500 fell 0.03% and the Nasdaq lost 0.09%, Reuters said. The indexes were still higher on the week. Reuters

Industrial gases peers were mixed, with Air Products closing up 0.64% on Dec. 26, Wall Street Journal data showed. Wall Street Journal

Linde supplies gases such as oxygen and nitrogen used across manufacturing, healthcare and electronics, leaving the stock sensitive to shifts in industrial activity but often less volatile than commodity-linked materials producers.

The stock traded between $423.41 and $426.00 on Dec. 26 and sits in a 52-week range of $387.78 to $486.38, according to MarketWatch. MarketWatch

Before next session, investors will be watching whether year-end portfolio adjustments and light holiday volumes keep market moves choppy when U.S. trading resumes on Monday. Reuters has noted that thin volumes can exaggerate price swings. Reuters

A key macro marker lands Tuesday (Dec. 30), when the Federal Reserve releases minutes from its December policy meeting — a detailed record investors comb for clues on the rate outlook. Reuters

Markets are focused on the pace of future rate cuts after the Fed lowered its benchmark rate by 75 basis points over its last three meetings of 2025 to 3.50%–3.75%, Reuters reported. Reuters

For Linde, the next major scheduled catalyst is its next quarterly report, which Nasdaq and Yahoo Finance list as an estimated Feb. 5 release date. Nasdaq

Investors will be listening for updated demand and pricing commentary, after Linde’s last earnings release forecast fourth-quarter adjusted earnings per share of $4.10 to $4.20 and full-year adjusted EPS of $16.35 to $16.45. Linde

Based on Friday’s close and MarketWatch’s 52-week range, Linde is about 12.7% below its 52-week high and about 9.5% above its 52-week low heading into the final week of the year. MarketWatch

Stock Market Today

  • Zimmer Biomet Shares Seen 47% Undervalued Amid Prolonged Price Weakness
    January 18, 2026, 5:49 PM EST. Zimmer Biomet Holdings (ZBH) shares closed at $87.31, reflecting a 19.5% drop over the past year amid ongoing market pressure. The stock's decline contrasts with broader healthcare peers, raising questions on fair valuation. A Two-Stage Discounted Cash Flow (DCF) model estimates intrinsic value at $165.31 per share, suggesting Zimmer Biomet is undervalued by approximately 47.2%. The DCF model uses projected free cash flow growth to 2028 and beyond. Investors assess whether sentiment overly discounts the firm's fundamentals despite solid cash flow estimates. The stock's valuation score stands at 5 out of 6, signaling potential value after sustained returns weakness. Zimmer Biomet's profitability and cash flows remain key factors in the valuation debate.
Boeing stock in focus before Monday after E-7 cost report, new airline buy plans
Previous Story

Boeing stock in focus before Monday after E-7 cost report, new airline buy plans

Caterpillar stock drifts into year-end as Fed minutes loom and trading stays thin
Next Story

Caterpillar stock drifts into year-end as Fed minutes loom and trading stays thin

Go toTop